697 results about "Binding domain" patented technology

The invention discloses a double-structural-domain recombinant human fibronectin, the sequence of which is shown as SEQ ID NO.3, and the double-structural-domain recombinant human fibronectin is formed by fusing a collagen binding structural domain and a cell binding structural domain of human fibronectin. The invention also provides a recombinant expression vector containing the protein coding gene and a host cell. The protein is efficiently expressed through eukaryotic cells and engineering bacteria escherichia coli, and a fermentation and purification process suitable for an industrial scale is established in a matched manner. Functional experiments prove that compared with commercially available fibronectin products with a single structural domain, the double-structural domain recombinant human chemical fibronectin disclosed by the invention can remarkably promote proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, skincare and biomedical materials.

Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-β ligand or a TGF-β receptor antibody. When present on chimeric antigen receptor (CAR)-bearing immune cells (CAR-T-cells), such receptors allow for increased CAR-T cell expansion, activity and persistence, constitutively and / or through engagement of a TGF-β ligand or a TGF-β receptor antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

The present invention relates to combination therapies employing tumor targeted anti-CEA / CD3 bispecific antibodies and / or agents blocking PD-L1 / PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules that also target FAP, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

The invention relates to an aptamer specifically combined with beta-lactoglobulin and application of the aptamer, and belongs to the technical field of biological detection. According to the aptamer and the preparation method thereof, a binding domain base, participating in recognition, of the aptamer is predicted through molecular docking firstly, then the binding domain base is subjected to directional mutation, the aptamer with the recognition performance improved is obtained, the affinity of the aptamer to beta-lactoglobulin is 10.6 nM, and the aptamer has no recognition capacity on alpha-lactalbumin, casein, bovine serum albumin, immune globulin G, lactose and the like and can be used for preparing the aptamer with the recognition performance improved. Therefore, the aptamer disclosed by the invention has good sensitivity and specificity on the beta-lactoglobulin. On the basis, a fluorescence polarization method is directly constructed by utilizing the characteristic that the beta-lactoglobulin is a biomacromolecule, when the beta-lactoglobulin exists, an aptamer marked by a fluorophore FAM recognizes the beta-lactoglobulin to form an aptamer beta-lactoglobulin compound, and the fluorescence polarization value is relatively large, so that the beta-lactoglobulin compound can be used for identifying the beta-lactoglobulin. Therefore, the specific detection of the low-concentration beta-lactoglobulin is realized.

The present disclosure relates to polypeptides comprising an antigen fragment of the receptor binding domain (RBD) of coronavirus spike glycoprotein, protein nanostructures thereof, methods of manufacture thereof, and prophylactic and therapeutic uses thereof. In various aspects, the antigen fragment comprises a coronavirus subdomain 1 (SD1).

Provided are anti-Claudin-6 antibodies (e.g., VHH domain antibodies), and a chimeric antigen receptor (CAR) that binds to Claudin-6 comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

Provided herein are binding molecules comprising a human neonatal Fc receptor (FcRn) binding molecule and at least one antigen-binding domain linked to the FcRn binding molecule. Polynucleotides, vectors, host cells, and methods of production are also provided herein. Methods of treating an antibody-mediated disorder with an FcRn / antigen-binding molecule are further provided.

The invention relates to a bispecific antibody and application thereof. The bispecific antibody comprises a first binding domain and a second binding domain.

The present invention relates to nucleic acids and modified immune cells or precursors thereof, comprising a first polynucleotide encoding an NF-κB p65-rTetO fusion protein comprising one or more transactivation domains (TAD) of human NF-κB p65 fused to a reverse Tet operator (rTetO) binding domain; a second polynucleotide comprising a Tet operator region (TetOR) for providing inducible expression of one or more transgene(s) operatively linked thereoto; and a third polynucleotide comprising a promoter directing transcription of p65-rTetO from a first strand of DNA, where the p65-rTetO is configured to induce transcription of a transgene of interest operatively linked to the TetOR in the presence of tetracycline or doxycycline (Dox) from an opposite strand of DNA.

The present disclosure provides CD19 / CD20-binding domains and chimeric antigen receptors (CARs) based on the same, as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, e.g., for the prevention and / or treatment of cancer and / or autoimmune disease.

Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an EC50 of about 10 nM or less, and / or are capable of promoting complement deposition on the target antigen with an EC50 of about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and / or therapeutically beneficial.

This disclosure provides an antibody (or antigen-binding protein) comprising at least one, preferably two, antigen-binding domains that bind to the human IL-6 receptor, wherein the antibody inhibits IL-6 transsignaling via the human soluble IL-6 receptor while maintaining IL-6 classical signaling via the human membrane-bound IL-6 receptor, and the antibody is capable of binding to both the human soluble IL-6 receptor and the human membrane-bound IL-6 receptor. Compositions comprising the antibody or antigen-binding protein are also provided, along with encoding nucleic acid molecules and expression vectors.

The present application provides an isolated antigen-binding protein, comprising: a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain specifically binds to TNF-like protein A (TL1A), and the first antigen binding domain and the second antigen binding domain are different.

This invention relates to an anti-FGFR2 / PD-1 bispecific antibody. The anti-FGFR2 / PD-1 bispecific antibody of the present invention comprises a first antigen-binding domain D1 and a second antigen-binding domain D2, where D1 is an anti-FGFR2 antibody or its antigen-binding fragment, and D2 is an anti-PD-1 antibody or its antigen-binding fragment. The anti-FGFR2 / PD-1 bispecific antibody of the present invention exerts an antitumor effect by suppressing the proliferation of FGFR2 target cells, killing target cells through ADCC activity, and simultaneously inhibiting the binding of PD-1 to its ligand, thereby releasing the inhibitory state of T cells.

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

The present invention relates to lipid-based nanoparticles comprising an antigen-binding domain capable of specifically binding to a target expressed on the surface of activated immune cells, and one or more mRNA molecules encoding an activity-enhancing protein of the activated immune cells, and to the use thereof.

The present invention relates to compositions targeting epidermal growth factor receptors and methods of making and using the same, and particularly provides antibody binding domains for the differentiation cluster 3 T cell receptor (CD3), antibody binding domains for the epidermal growth factor receptor (EGFR), cleavable linker sequences, and protease activatable bispecific fusion proteins, a T cell adaptor, such as a protease, can be activated, as well as uses and methods of treatment.

The invention relates to a CD19 and CD70 targeted double-target chimeric antigen receptor and application thereof, the CD19 and CD70 targeted double-target chimeric antigen receptor comprises an extracellular antigen binding domain, a hinge region, a transmembrane domain, an intracellular costimulatory domain and an intracellular signal transduction domain, and the extracellular antigen binding domain has specific binding ability to CD19 and CD70. The double-target chimeric antigen receptor structure has a treatment effect of targeting double antigens or single antigens, can be used for preparing immune effector cells targeting CD19 and CD70, and provides a treatment or improvement approach for diseases related to CD19 and CD70 double expression or CD19 / CD70 single expression.

The present disclosure is directed to antibody drug conjugates (ADCs) comprising an antibody or antigen binding fragment thereof that binds IL-1RAP. The ADCs of the present disclosure are useful for, among other things, treating diseases with upregulated IL-1RAP expression.

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.

Provided herein are engineered IgA antibodies that comprises: (a) an EGFR binding domain and (b) an IgA heavy chain constant region. Also, provided herein are methods of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the engineered antibody.

This invention relates to the field of biopharmaceutical manufacturing technology, and discloses a BCMA-targeting nanobody, its preparation method, and its application. The nanobody comprises a heavy chain single-domain binding domain, a helical conformation-constrained peptide chain, and an amphiphilic self-assembled polypeptide sequence. The helical conformation-constrained peptide chain forms a steric barrier between the binding domain and the polypeptide sequence through physical length, maintaining the monomeric conformation of the polypeptide sequence in a free state. When the binding domain is anchored at the receptor binding interface, the conformation-constrained peptide chain increases the local effective concentration of the polypeptide sequence within the confined space, inducing intermolecular topological assembly. This invention utilizes a kinetic phase transition mechanism to generate a binding state jump, maintaining the conformational activity of the composition in the circulatory system, reducing off-target toxicity, and prolonging the residence time at the receptor interface.

The present application relates to a bivalent new coronavirus vaccine, a preparation method and uses thereof, the bivalent new coronavirus vaccine comprises a fusion protein, the fusion protein comprises a receptor binding domain (RBD) of S protein of a first new coronavirus mutant or a functional fragment thereof, an immunoglobulin Fc and a receptor binding domain (RBD) of S protein of a second new coronavirus mutant or a functional fragment thereof, the first new coronavirus mutant and the second new coronavirus mutant are different mutants. The vaccine can significantly improve the neutralizing antibody titer against the new coronavirus Delta mutant and the Omicron mutant.

This disclosure relates to an antibody or fragment thereof comprising an antigen-binding domain capable of binding to a CDS protein or fragment thereof. This disclosure also relates to such antibodies that bind to CDS having an affinity optimized for inducing T cell activation but without being associated with excessive cytokine release and decreased tolerance. This disclosure also relates to methods for producing these antibodies and their therapeutic use.

The present disclosure relates to recombinant nucleases, recombinant nucleases operatively linked to nucleic acid binding domains, and methods of making and using them.

The present application relates to the technical field of biology and medicine, and particularly relates to a ULBP2 specific chimeric antigen receptor, a CAR-T cell and application thereof. The ULBP2 specific chimeric antigen receptor comprises a ULBP2 antigen binding domain, a transmembrane domain and an intracellular signaling domain, and the ULBP2 antigen binding domain comprises an amino acid sequence as shown in SEQ ID NO: 1. After the ULBP2 specific chimeric antigen receptor is transduced into lymphocytes, the killing ability of the lymphocytes on tumor cells is significantly enhanced, and the lymphocytes have a significant directional killing effect on tumor cells with high expression of ULBP2. The present application also relates to application of the ULBP2 specific CAR-T cell in combination with an anti-PD1 antibody for treating cancer.

The present invention provides a combination comprising a) an antigen binding domain specific for CD90, and b) an antigen binding domain specific for CD326, for use in treatment of human cancer comprising cancerous cells that co-express CD90 and CD326. In one embodiment of the invention the combination comprises a) an immune cell comprising a CAR comprising an antigen binding domain specific for a tag of a first and a second polypeptide, b) said tagged first polypeptide that has an antigen binding domain specific for CD90, and c) said tagged second polypeptide that has an antigen binding domain specific for CD326, wherein the tag of the first polypeptide and the tag of the second polypeptide are identical. In a further embodiment the concentrations used for said first and that second polypeptide are below the activation threshold of said CAR, respectively, but the sum of both concentrations is above the activation threshold of said CAR.